Complementation can maintain a quasispecies of drug sensitive and resistant HIV

Laurelle Jackson^{1,2}, Sandile Cele¹, Gila Lustig¹, Jennifer Giandhari³, Tulio de Oliveira³, Richard A. Neher⁴, Alex Sigal^{1,2,5*}

*For correspondence:
alex.sigal@ahri.org (AS)

¹Africa Health Research Institute, Durban, South Africa; ²School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa; ³KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa; ⁴Biozentrum and SIB Swiss Institute of Bioinformatics, University of Basel, Basel, Switzerland; ⁵Max Planck Institute for Infection Biology, Berlin, Germany

Abstract HIV exists as multiple genotypes in a single infected individual referred to as a quasispecies. Here we reproduced a quasispecies by moderate selective pressure using an HIV reverse transcriptase inhibitor. The drug resistant genotype never completely supplanted the drug sensitive genotype, which stabilized at about 20 percent of viral sequences. Single-cell sequencing showed that resistant genotype frequency plateaued when cells were co-infected with sensitive and resistant genotypes, suggesting a sharing of viral proteins in co-infected cells (complementation) which masks genotypic differences. To test if complementation can confer phenotypic drug resistance, we co-transfected fluorescently labelled molecular clones of sensitive and resistant HIV and observed that genotypically sensitive virus from co-transfected cells was drug resistant. Resistant virus preferentially infected cells in tandem with drug sensitive HIV, explaining how co-infections of sensitive and resistant genotypes were initiated. Modelling this effect, we observed that a stable quasispecies could form at the experimental multiplicities of infection for the drug resistant and drug sensitive virus, showing that complementation can lead to a quasispecies in an HIV evolution experiment.

Introduction

The HIV quasispecies consists of multiple viral genomes sampled from a compartment such as blood. One consequence of a quasispecies is diversity in the HIV Env gene. This allows HIV to escape neutralizing antibodies *Frost et al. (2005); Rong et al. (2009)*. In the face of antiretroviral therapy, a quasispecies is formed which results in a mixture of HIV genomes that are resistant to different degrees to antiretroviral drugs (ARVs) *Brenner et al. (2002); Allers et al. (2007); Samuel et al. (2016)*. A quasispecies may also allow HIV to maintain sufficient heterogeneity to escape effective T cell suppression *Phillips et al. (1991); Goulder et al. (2001)*.

Due to the errors in reverse transcription, HIV replication generates a quasispecies where variants are at low frequencies around the main viral sequence *Brenner et al. (2002); Coffin (1992); Katz and Skalka (1990)*. Selection should act to clear less fit variants *Rosenbloom et al. (2012)*, so how a stable quasispecies with different variants at high frequencies is maintained is unclear. One possibility is that different anatomical compartments apply different selective pressures, therefore leading to a diverse viral pool *Paranjpe et al. (2002); Schnell et al. (2010)*. A mechanism to create a

quasispecies that does not rely on the assumption of different compartments is complementation or phenotypic mixing *Domingo et al. (2012); Hill et al. (2012)*. With this mechanism, co-infection and viral protein expression from two different viral genotypes in the same cell results in sharing of viral components. This mechanism is distinct from recombination, where two viral genomes co-packaged in the same cell recombine to form a new genome *Levy et al. (2004)*. In complementation, a virus of genotype 1 may contain proteins from virus of genotype 2 and vice versa (Figure 1). If one of the genotypes has a fitness cost relative to the other, the difference in fitness will be masked *Andino and Domingo (2015)*. This process has been postulated to operate in viruses *Froissart et al. (2004); Vignuzzi et al. (2006)* including HIV *Mo et al. (2004); Gelderblom et al. (2008)*. There is no known mechanism which prevents one HIV genotype packaging viral proteins such as reverse transcriptase (RT) from another HIV genotype if both genotypes are expressed in the same cell, since RT molecules mix in the cell cytoplasm *Freed (2001)*.

Figure 1. Schematic of how drug sensitive and drug resistant HIV could co-exist by complementation in the face of selective pressure applied by a reverse transcriptase inhibitor. When drug sensitive and drug resistant virus infect separate cells, the virus genotype corresponds to the virus phenotype (left two panels). When a drug sensitive and drug resistant virus infect the same cell, the virions produced will have either a drug sensitive or drug resistant genotype but similar numbers of drug resistant and drug sensitive reverse transcriptase molecules, and hence the same phenotypic drug resistance (right panel).

Here we used *in vitro* HIV evolution in the presence of the RT inhibitor efavirenz (EFV) to determine whether a quasispecies can be formed in a homogeneous infection environment. We used a concentration of drug which allowed drug sensitive virus to replicate, but conferred a strong fitness advantage to drug resistant virus. We observed that drug resistance evolved during infection in the face of EFV. Initially, viral genotypes with drug resistance mutations expanded rapidly. However, once the fraction of drug resistance mutant infected cells reached approximately 80%, the frequency of drug sensitive virus stabilized. This correlated with co-infection of drug sensitive and drug resistant genomes, and such co-infection led to virions with drug sensitive and drug resistant genotypes to display a similar level of EFV resistance. Therefore, complementation can maintain a quasispecies of viral variants having different fitness in the presence of drug.

Results

To test whether a quasispecies can be reproduced *in vitro*, we infected cells from an HIV reporter cell line in the face of drug pressure from EFV. As the reporter cells we used the RevCEM E7 clone (*Boullé et al. (2016); Jackson et al. (2018)*) from the RevCEM GFP reporter cell line. These cells express GFP in the presence of the HIV Rev protein (*Wu et al. (2007)*), with the maximum frequency of GFP positive cells being about 70 percent in the E7 clone (*Jackson et al. (2018)*). Infection was initiated with 4 days (approximately 2 viral cycles) of infection in the absence of drug. Drug was then added (day 0) and infection measured every two days. After the frequency of infected cells was recorded, infection was diluted to 2% of the total cell population by addition of uninfected cells. This enabled us determine the degree to which infection could expand in each 2 day infection cycle without exhausting the population of uninfected target cells.

74 The EFV concentration used was 20nM. This allowed drug sensitive (wildtype) HIV to persist
75 (Figure 2A). The number of cells infected in a two day infection cycle starting at 2% infected cells
76 began to increase at day 6 post-addition of EFV selective pressure (Figure 2A). An increase in the
77 number of infected cells is expected with the evolution of drug resistance.

78 To examine whether evolution of drug resistance did take place, we sequenced the infected cell
79 population and determined the fraction of sequences with drug resistance mutations. Sequencing
80 of the HIV DNA from the infected cell population showed that starting day 6 post-drug addition,
81 mutations in the HIV RT gene which confer resistance to EFV were detected (Figure 2B, see Figure
82 S1 for individual independent experiments and the mutations which arose). Predominant among
83 these was the L100I mutation (Figure S1), conferring moderate resistance to EFV *Jackson et al.*
84 (2018). The frequency of mutant genotypes reached about 80% on day 10. The combined frequency
85 of the mutants stabilized at about 80% on day 12 and day 14. Drug sensitive HIV accounted for the
86 remaining 20 percent of sequences in the population.

Figure 2. EFV resistant mutants do not completely supplant drug sensitive viral sequences in the face of EFV selection. (A) Frequency of infection as a function of time in the presence of 20nM EFV. Cells were cultured for two infections cycles before the addition of drug (day 0). Thereafter, the frequency of infection was measured every 2 days. Mean $\pm$ SEM of 3 independent experiments. (B) Frequency of EFV resistant mutants as a function of time derived from illumina sequencing of the cell populations from (A). Mean $\pm$ SEM of 3 independent experiments. Dotted line marks frequency of 0.8.

87 To examine whether the plateau in the frequency of drug resistant mutants was correlated
88 with co-infection of the same cell with wildtype and mutant HIV, we single-cell sequenced HIV DNA
89 in 30 to 60 cells by sorting GFP positive infected cells into wells of a multi-well plate at 1 cell per
90 well, then lysing and amplifying the RT region followed by illumina sequencing (Figure 3). At day
91 0, before selective pressure was applied, all infected cells showed wildtype HIV genomes. At day
92 6, 35% of cells had EFV resistance mutations. On day 8 and day 14, where the mutant frequency
93 stabilized at about 80% in the population measurement, the majority of cells were infected by EFV
94 resistant mutants. On all days where drug resistant mutant infection was present, individual cells
95 also contained wildtype sequences. At later time points, there was an increase in cells infected
96 with multiple drug resistance mutant genomes. There was greater than expected frequency of
97 the G190A mutation relative to the population data, but this was mostly explained by variation in
98 mutant frequencies between experiments (Figure S1), with the single-cell sequences originating
99 in an experiment which showed higher frequencies of G190A at the population level (Figure S1,
100 experiment 3).

Figure 3. Sequencing of viral genomes in single cells shows increasing frequency of co-infected cells with time. Shown are the relative frequencies of wildtype and mutant HIV genomes per cell for the day 0, day 6, day 8 and day 14 post-EFV addition. Frequency is on the x-axis, cell number on y-axis. Cells were ranked by lowest to highest wildtype frequency. Dark grey is the wildtype genotype, blue is the L100I mutant, orange is the K103N mutant, green is the G190A mutant, and light grey is the L100I/G190A linked double mutant.

To directly test whether an EFV resistant mutant HIV can complement wildtype, we used transfection of molecular viral clones consisting of plasmids expressing a mutant and wildtype virus in conjunction with a fluorescent protein. Upon transfection, molecular clones produce fully functional replicating virus which can be tested for resistance to EFV. This system offers direct control over co-expression of viral proteins in the same cell, as wildtype and mutant virus expressing plasmids can be transfected separately or mixed for efficient co-transfection. We transfected molecular clones expressing either wildtype CFP labeled virus (*Levy et al. (2004)*) or YFP labelled virus in which we replaced the RT region with the L100I mutant into a virus producer cell line. The producer cells showed either CFP or YFP fluorescence, depending on the transfected virus (Figure 4A, left panel). When we co-transfected the molecular clones, we observed dual CFP and YFP expression from most fluorescent cells, indicating both viral strains being expressed from the same cell (Figure 4A, right panel). We collected viral supernatant from each of the three conditions, filtered the viral supernatant to avoid any carryover of transfected cells, and used it to infect the lymphocytic MT4 cell line (see Figure S2 for gating strategy). To quantify infection under equivalent detection conditions, we mixed the supernatants from the single genotype transfected, wildtype only CFP expressing cells, and single genotype transfected, mutant only YFP expressing cells. We compared this infection to that of supernatant from the wildtype/mutant co-transfected cells. The EFV sensitivity of each genotype in a mixed infection could then be tracked based on the decrease of CFP (wildtype) expressing cells or YFP (mutant) expressing cells with escalating EFV concentration (see Figure S2 for gating strategy). Cells infected with virus made from mixed single genotype transfections were either EFV sensitive (wildtype, CFP expressing cells) or resistant (mutant, YFP expressing cells) (Figure 4B, left panel). In contrast, virus from the co-transfection showed EFV resistance for both the wildtype CFP expressing genotype and the YFP expressing mutant genotype (Figure 4B, right panel). For wildtype, resistance gained was comparable to the YFP resistant mutant. This indicates that

Figure 4. Co-transfection of wildtype and mutant molecular clones yields resistant virus independent of genotype. (A) CFP expressing wildtype and YFP expressing L100I EFV resistant mutant molecular clones were either transfected separately (left) or co-transfected (right) into a virus producer cell line. Shown are images after producer line transfection, with CFP in red and YFP in green. Co-transfected cells which express both fluorescent proteins are yellow. (B) Sensitivity of cell-free virus collected from the transfections to EFV. Sensitivity was measured as the transmission index (Tx), the ratio of the number of infected cells in the presence of EFV divided by the number of infected cells in the absence of EFV for each genotype. Wildtype (CFP labelled) and mutant (YFP labelled) genotypes were determined by the corresponding fluorescence. Left panel shows a mix of wildtype and mutant virus from separate transfections, while right panel shows virus from co-transfection. Red and blue points are the Tx values of mutant and wildtype genotypes respectively (mean $\pm$ std of 3 independent experiments). (C) Predicted fraction of virions containing at least one mutant RT molecule as a function of the ratio of genomic copies of drug sensitive versus resistant virus and the number of RT molecules packaged.

the wildtype virus was able to complement with the mutant virus.

We calculated the probability that at least one molecule of mutant RT is packaged per virion in co-infected cells as a function of the number of RT molecules packaged per virion and the ratio of wildtype to mutant viral genomes, assuming each genome produces the same number of RT proteins. At low numbers of RT molecules and high number of wildtype genomes, the probability that mutant RT will be packaged is low and complementation should be rare. At the reported numbers of RT molecules per virion (roughly 50) (Panet and Kra-Oz (1978); Bauer and Temin (1980)), the fraction of co-packaging virions and therefore complementation is high (Figure 4C).

Figure 5. Double infection is more frequent than expected assuming independence. (A) CFP labelled wildtype HIV the YFP labelled mutant were used to infect non-reporter C7 target cells in the absence of drug. Infection was titrated to yield different wildtype frequencies, and the percent of double infected cells detected in the top right quadrant. (B) The measured (black squares) versus expected (grey squares) percentage of double infection at different wildtype frequencies. Expected probability of double infection was calculated as the product of the wildtype and mutant single infection frequencies. Mean $\pm$ SEM from 3 independent experiments.

Whether co-infection is common has been an area of active debate (Jung et al. (2002); Law et al. (2016); Josefsson et al. (2011, 2013)). However, it was previously observed that HIV preferentially co-infects cells at relatively low infection frequencies (Dang et al. (2004); Del Portillo et al. (2011)), possibly due to heterogeneity in the cell population, cooperativity between viruses, or other factors. To test for this, we infected a RevCEM clone selected for lack of GFP expression (Materials and methods) with CFP expressing wildtype virus or YFP expressing L100I mutant (Figure 5A). We observed co-infection frequencies which were approximately one-order of magnitude higher than predicted under the assumption that infections were independent (Figure 5B, see Figure S3 for flow cytometry plots). This effect was even stronger in peripheral blood mononuclear cells (Figure S4) when these cells were infected in the presence of a cell line expressing the DC-SIGN receptor. DC-SIGN binds HIV on the surface. Infection with surface bound virus is efficient (Kim et al. (2018)) and is important in environments such as the germinal center of the lymph node (Fletcher et al. (2014)). Hence, a high frequency of co-infection need not be common overall and may be localized to specific environments.

To investigate whether a stable quasispecies is predicted to occur given experimentally measured parameter values, we simulated the frequencies of wildtype, mutant and co-infected cells through time (Materials and methods). The experimentally measured values for the multiplicity of infection were calculated as $R_0 I_{input} / T$, where R_0 is the basic reproductive ratio for wildtype or mutant, measured at an input of 0.2% infected cells (Figure S5, Tables S1 and S2), I_{input} the input number of wildtype or mutant infected cells, and T the number of uninfected cells. The assumption was made in the model that a cell co-infected with mutant and wildtype virus would produce half of the virions with a wildtype genotype and half with mutant, and that these would contain sufficient drug resistant RT to be phenotypically mutant, consistent with a high number of RT molecules per virion (Figure 4C). We observed that at the experimentally measured values, cells infected with mu-

157 tant virus did not entirely supplant wildtype infected cells. There was a high and stable frequency
158 of both co-infected cells and a lower but stable frequency of wildtype only infected cells (Figure 6A).
159 Examining these effects as a function of multiplicity of infection of the mutant virus showed that
160 the frequency of wildtype infected cells (sum of co-infections with mutant and wildtype only) were
161 absent at mutant multiplicities of infection below approximately 2 and sharply increased there-
162 after. This effect can be explained by the requirement of wildtype infected cells to be co-infected
163 by mutant at high frequencies for the wildtype not to be outcompeted.

Figure 6. Model of complementation shows that a stable quasispecies is predicted at the experimentally measured parameter values. (A) Predicted frequencies of wildtype infected (wt, blue line), drug resistant mutant infected (mt, red line), and coinfecting wildtype-mutant (coinfect, yellow line) cells over 50 viral cycles (approximately 100 days). (B) The fraction of cells infected with wildtype after 500 viral cycles, both as wildtype only and co-infected with mutant, as a function of mutant multiplicity of infection. Multiplicity of infection is calculated as $(R_{mt} I_{input}^{mt} + 0.5 R_{mt} I_{input}^{co}) / T$, where R_{mt} is the measured R_0 for mutant, I_{input}^{mt} is the input number of mutant infected cells, I_{input}^{co} is the number of input co-infected cells, and T is the number of uninfected target cells.

164 Discussion

165 We observed that a quasispecies is formed in the face of EFV selective pressure, where wildtype HIV
166 persists despite a fitness disadvantage relative to drug resistant virus. The necessary condition for
167 complementation to occur *in vivo* is expression of multiple viral genotypes in the same cell. Multiple
168 infections can occur by cell-to-cell spread, a directed mode of HIV transmission efficiently delivering
169 HIV from the donor to target cell (Jolly *et al.* (2004); Sattentau (2008); Sigal *et al.* (2011); Jackson
170 *et al.* (2018); Agosto *et al.* (2015); Abela *et al.* (2012); Baxter *et al.* (2014); Boullé *et al.* (2016); Hübner
171 *et al.* (2009); Del Portillo *et al.* (2011); Iwami *et al.* (2015); Duncan *et al.* (2013); Groot *et al.* (2008);
172 Sherer *et al.* (2007); Zhong *et al.* (2013)), likely to occur in localized environments with minimal
173 flow to disrupt cellular interactions (Sourisseau *et al.* (2007)). HIV can be transmitted by cell-to-cell
174 spread to multiple cells at once (Rudnicka *et al.* (2009)). Therefore, one cell can be infected by
175 multiple HIV genomes if there are multiple HIV transmitting cells in its vicinity.

176 The frequency of multiple HIV proviruses per cell has been controversial, with some studies
177 showing multiple infection per cell (Jung *et al.* (2002); Law *et al.* (2016); Gratton *et al.* (2000)). Other
178 studies did not show multiple infections at a frequency greater than that predicted by the Poisson
179 distribution (Josefsson *et al.* (2011, 2013)). Given that many proviruses are not expressed (Bruner
180 *et al.* (2016)) and that cells with multiple infections may be more likely to express HIV and be infec-
181 tious (Wodarz and Levy (2017)), it is possible that the multiplicity of infection may be higher than
182 predicted by Poisson in cells where HIV is actively replicating (Pardons *et al.* (2019)). Other possi-
183 bilities where localized multiple infection per cell can occur is in cell subsets (Banga *et al.* (2016))
184 where HIV infection is particularly efficient in lymph nodes or gut (Fletcher *et al.* (2014); Brenchley

185 *et al. (2004); Deleage et al. (2016))*.

186 Complementation can reduce the fitness of the viral population by preventing the selection
187 of more fit genotypes (*Froissart et al. (2004)*). There is evidence that the quasispecies stabilized
188 by complementation is beneficial for the fitness of the population, since this allows deleterious
189 variants to share components and result in a more functional virion, or keep a heterogeneous
190 pool of virus which can react to rapid changes in the infection environment (*Vignuzzi et al. (2006);*
191 *Domingo et al. (2012); Lauring et al. (2013); Andino and Domingo (2015)*). Interestingly, the majority
192 mutant HIV in this study was coinfecting with wildtype. This may indicate that wildtype infection may
193 make the cells more permissive for the L100I mutant.

194 Complementation may be one example of how the quantitative parameters of infection, and
195 specifically the infecting dose (*Moyano et al. (2020); Sigal et al. (2011); Wodarz and Levy (2017)*), may
196 change the nature of infection and how it responds to inhibitors. The relatively high multiplicity of
197 infection required for complementation need not be pervasive nor occur due to a very high R_0 , but
198 may also be the result of a high concentration of infected donor relative to yet uninfected target
199 cells. This study shows that HIV complementation can occur and lead to a quasispecies under
200 conditions where the multiplicity of infection can be experimentally controlled. The extent this
201 effect occurs *in vivo* is yet to be determined.

202 **Methods and Materials**

203 **Inhibitors, viruses and cell lines**

204 The antiretroviral EFV, Raji cells and Raji-DC cells were obtained from the AIDS Research and Refer-
205 ence Reagent Program, National Institute of Allergy and Infectious Diseases, National Institutes of
206 Health. RevCEM cells from Y. Wu and J. Marsh; MT-4 cells from D. Richman and HIV molecular clone
207 pNL4-3 from M. Martin. The NL4-3YFP and NL4-3CFP molecular clones were gifts from D. Levy. Cell-
208 free viruses were produced by transfection of HEK293 cells with pNL4-3 using TransIT-LT1 (Mirus)
209 or Fugene HD (Roche) transfection reagents. Virus containing supernatant was harvested after two
210 days of incubation and filtered through a 0.45 μ m filter (Corning). The number of virus genomes
211 in viral stocks was determined using the RealTime HIV-1 viral load test (Abbott Diagnostics). The
212 L100I mutant was evolved by serial passages of wildtype NL4-3 in RevCEM cells in the presence of
213 20nM EFV. After 18 days of selection, the RT gene was cloned from the proviral DNA and the mutant
214 RT gene was inserted into the NL4-3 molecular clone. RevCEM clone E7 and G2 used in this study
215 were generated as previously described *Boullé et al. (2016)*. Briefly, the E7 clone was generated
216 by subcloning RevCEM cells at single cell density. Surviving clones were subdivided into replicate
217 plates. One of the plates was screened for the fraction of GFP expressing cells upon HIV infection
218 using microscopy, and the clone with the highest fraction of GFP positive cells was selected. As
219 with the E7 clone, for the generation of the RevCEM clone C7, cells were split into single cell density
220 and one of the plates were screened for the lowest fraction of GFP expression upon HIV infec-
221 tion. The clone with lowest fraction of GFP was selected. All cell lines not authenticated, and my-
222 coplasma negative. Cell culture and experiments were performed in complete RPMI 1640 medium
223 supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential amino acids (Lonza), and
224 10 percent heat-inactivated FBS (Hyclone). For transfections of CFP and YFP viruses, NL4-3YFP and
225 NL4-3CFP were added to Fugene HD (Roche) for single transfections co-transfection into HEK293
226 cells.

227 **Primary cells**

228 Blood for PBMC was obtained from HIV negative blood donors with no TB symptoms. Informed
229 consent was obtained from each participant, and the study protocol approved by the University
230 of KwaZulu-Natal Institutional Review Board (approval BE083/18). PBMCs were isolated by density
231 gradient centrifugation using Histopaque 1077 (Sigma-Aldrich) and cultured at 10^6 cells/ml in com-
232 plete RPMI 1640 medium supplemented with L-Glutamine, sodium pyruvate, HEPES, non-essential

233 amino acids (Lonza), 10 percent heat-inactivated FBS (GE Healthcare Bio-Sciences), and IL-2 at 5
234 ng/ml (PeproTech). Phytohemagglutinin at 10 μ g/ml (Sigma-Aldrich) was added to activate cells.

235 Staining and flow cytometry

236 The frequency of RevCEM E7 GFP positive cells was detected on a FACSCaliber (BD Biosciences)
237 machine using the 488 laser lines. The number of CFP and YFP positive cells was determined on
238 an FACSAriaIII (BD Biosciences) using the 405nm and 488nm laser lines. Results were analysed with
239 FlowJo 10.0.8 software. For single cell sorting to detect the number of HIV DNA copies per cell, GFP
240 positive cells were single cell sorted using 85 micron nozzle in a FACSAriaIII machine into 96 well
241 plates (Biorad) containing 30 μ l lysis buffer (2.5 μ l 0.1M Dithiothreitol, 5 μ l 5 percent NP40 and 22.5 μ l
242 molecular biology grade water.

243 Deep sequencing

244 For single cells, the cells were lysed and DNA was kept suspended in the lysis buffer. For pop-
245 ulations of cells, genomic DNA was extracted using the QIAamp DNA mini kit (Qiagen). Phusion
246 hot start II DNA polymerase (New England Biolabs) PCR reaction mix (10 μ l 5X Phusion HF buffer,
247 1 μ l dNTPs, 2.5 μ l of the forward primer, 2.5 μ l of the reverse primer, 0.5 μ l Phusion hot start II
248 DNA polymerase, 2.5 μ l of DMSO and molecular biology grade water to 50 μ l reaction volume) was
249 added to the lysed single cells or extracted genomic DNA of cell populations. Two rounds of PCR
250 were performed. The first-round reaction amplified a region of the RT gene in the proviral DNA
251 using the forward primer 5' tcgtcggcagcgatgtgtataagagacagTTAATAAGAGAACTCAAGATTTC 3'
252 and reverse primer 5' gtctcgtgggctcggagatgtgtataagagacagCCCCACCTCAACAGATGTTGTC 3'. Non-
253 capitalized portion of the primers represent the Nextera® XT Index Kit adaptors. Cycling program
254 was 98°C for 30 seconds, then 35 cycles of 98°C for 10 seconds, 50°C for 30 seconds and 72°C
255 for 15 seconds with a final extension of 72°C for 5 minutes. 1 μ l of the first round product was
256 then transferred into a PCR mix as above, with second round Nextera XT Index Kit adaptor primers
257 (forward 5' tcgtcggcagcgatgtgtataagagacag 3', reverse 5' gtctcgtgggctcggagatgtgtataagagacag
258 3'). The second round PCR amplified a 400bp product which was then visualized on a 1% agarose
259 gel. The PCR amplicon was gel extracted using the QIAquick gel extraction kit (Qiagen). Illumina
260 indices were attached to the amplicon with the Nextera XT Index Kit and deep sequenced using
261 the Illumina Miseq. Fast-q files were analysed in Geneious. Both 5' and 3' ends were trimmed with
262 an error probability limit of 0.1. Drug resistant mutations were found based on a minimum variant
263 frequency of 0.01 for populations of cells and 0.05 for single cells. The maximum variant P-value
264 was 10^{-6} .

265 Evolution

266 Experiments were initiated with a cell-free infection, where 10^6 cells/ml RevCEM E7 were infected
267 with 2×10^8 NL4-3 viral copies/ml (roughly 20ng p24 equivalent) for 2 days. Infected cells from the
268 cell-free infection were used as the donors and cocultured with 10^6 cells/ml target cells. After two
269 days of infection, 2% of the infected cells were added to uninfected target cells and cocultured for a
270 2-day cycle (day 0). Thereafter, 2% of resuspended infected cells were added to uninfected targets
271 in the presence of EFV and co-cultured for each 2-day cycle.

272 Frequency of CFP and YFP double infections

273 10^6 RevCEM clone C7 cells/ml were infected with 2×10^8 wildtype NL4-3CFP viral copies/ml (roughly
274 20ng p24 equivalent) for 2 days. Infected cells from the cell-free infection were used as the donors
275 and cocultured with 10^6 cells/ml C7 uninfected target cells at ratios of 1:5, 1:10, 1:50 and 1:100.
276 The L100I mutant NL4-3YFP virus was added at 1:50 dilution (roughly 2ng p24 equivalent) to each
277 wildtype NL4-3CFP donor to target condition. Cells were incubated for 2 days and analysed by flow
278 cytometry. For the Raji and Raji-DC experiments, Raji cells and Raji-DC cells were added to PBMCs

at ratios of 1:2 and then infected with 2×10^8 NL43-YFP and NL43-CFP viral copies/ml (roughly 20ng p24 equivalent) for 2 days and analyzed by flow cytometry.

Simulation of the fraction of cells containing mutant RT

A stochastic simulation was performed to find the probability of a virus packaging at least one mutant RT molecule as a function of the total number of RT molecules packaged by one virus and the fraction of RT molecules in the cell produced by the mutant RT gene. A vector of random numbers with number of entries equal to the number of total RT molecules packaged was chosen using Matlab from a uniform distribution between 0 and 1. If at least one of the numbers was less than $1 - F_{wt}$, where F_{wt} is the wildtype frequency, the iteration was scored as containing at least one mutant RT. 10^4 iterations were performed for each combination of total RT molecules and F_{wt} , and the frequency of iterations with at least one mutant RT graphed.

Simulation of wildtype, mutant and co-infected cell frequencies

Measured or set parameter values were:

- Total number of cells (T) = 6×10^6
- Input of total infected cells at each viral cycle (I) = 1.2×10^5
- Input of mutant (I_{input}^{mt}), wildtype (I_{input}^{wt}), and co-infected (I_{input}^{co}) cells infected cells at viral cycle i are $I_{mt} = F_{mt} I$, $I_{wt} = F_{wt} I$, $I_{co} = F_{co} I$ where F_{mt} , F_{wt} , F_{co} are the fraction of mutant infected, wildtype infected, and co-infected cell and the end of infection cycle $i - 1$
- Mutant R_0 (R_{mt}) = 162
- Wildtype R_0 (R_{wt}) = 26

The multiplicity of infection for mutant and wildtype at infection cycle i with complementation was calculated as

$$M_i^{mt} = (R_{mt} I_{input}^{mt} + 0.5 R_{mt} I_{input}^{co}) / T,$$

$$M_i^{wt} = (R_{wt} I_{input}^{wt} + 0.5 R_{wt} I_{input}^{co}) / T.$$

The probabilities of cells being infected with mutant and wildtype 10^{-6} were:

$$P_{mt} = 1 - e^{-M_i^{mt}},$$

$$P_{wt} = 1 - e^{-M_i^{wt}}.$$

The probability of co-infection was therefore:

$$P_{co} = P_{mt} P_{wt}.$$

The number of co-infected cells in cycle i was:

$$I_{co} = P_{co} T.$$

The number of mutant only and wildtype only infected cells in cycle i was:

$$I_{mt} = P_{mt} T - I_{co},$$

$$I_{wt} = P_{wt} T - I_{co}.$$

The fraction of cells in each infection state (mutant, wildtype, co-infected) was therefore I_{mt}/T , I_{wt}/T , I_{co}/T respectively.

Acknowledgments

This work was supported by Research Group Leader funding from the Max Planck Society (AS).

References

- Abela IA**, Berlinger L, Schanz M, Reynell L, Günthard HF, Rusert P, Trkola A. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. *PLoS pathogens*. 2012; 8(4):e1002634.
- Agosto LM**, Uchil PD, Mothes W. HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapy. *Trends in microbiology*. 2015; 23(5):289–295.
- Allers K**, Knoepfel SA, Rauch P, Walter H, Opravil M, Fischer M, Günthard HF, Metzner KJ. Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo. *JAIDS Journal of Acquired Immune Deficiency Syndromes*. 2007; 44(4):377–385.
- Andino R**, Domingo E. Viral quasispecies. *Virology*. 2015; 479-480:46–51. <https://www.ncbi.nlm.nih.gov/pubmed/25824477>, doi: 10.1016/j.virol.2015.03.022.
- Banga R**, Procopio FA, Noto A, Pollakis G, Cavassini M, Ohmiti K, Corpataux JM, de Leval L, Pantaleo G, Perreau M. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. *Nat Med*. 2016; 22(7):754–61. <https://www.ncbi.nlm.nih.gov/pubmed/27239760>, doi: 10.1038/nm.4113.
- Bauer G**, Temin HM. Specific antigenic relationships between the RNA-dependent DNA polymerases of avian reticuloendotheliosis viruses and mammalian type C retroviruses. *J Virol*. 1980; 34(1):168–77. <https://www.ncbi.nlm.nih.gov/pubmed/6154804>.
- Baxter AE**, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ. Macrophage infection via selective capture of HIV-1-infected CD4+ T cells. *Cell host & microbe*. 2014; 16(6):711–721.
- Boullé M**, Müller TG, Dähling S, Ganga Y, Jackson L, Mahamed D, Oom L, Lustig G, Neher RA, Sigal A. HIV cell-to-cell spread results in earlier onset of viral gene expression by multiple infections per cell. *PLoS pathogens*. 2016; 12(11):e1005964.
- Brenchley JM**, Schacker TW, Ruff LE, Price DA, Taylor JH, Beilman GJ, Nguyen PL, Khoruts A, Larson M, Haase AT, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. *The Journal of experimental medicine*. 2004; 200(6):749–759.
- Brenner BG**, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. *Journal of virology*. 2002; 76(4):1753–1761.
- Bruner KM**, Murray AJ, Pollack RA, Soliman MG, Laskey SB, Capoferri AA, Lai J, Strain MC, Lada SM, Hoh R, Ho YC, Richman DD, Deeks SG, Siliciano JD, Siliciano RF. Defective proviruses rapidly accumulate during acute HIV-1 infection. *Nature medicine*. 2016; 22(9):1043.
- Coffin JM**. Genetic diversity and evolution of retroviruses. *Curr Top Microbiol Immunol*. 1992; 176:143–64. <https://www.ncbi.nlm.nih.gov/pubmed/1600751>.
- Dang Q**, Chen J, Unutmaz D, Coffin JM, Pathak VK, Powell D, KewalRamani VN, Maldarelli F, Hu WS. Nonrandom HIV-1 infection and double infection via direct and cell-mediated pathways. *Proceedings of the National Academy of Sciences*. 2004; 101(2):632–637.
- Del Portillo A**, Tripodi J, Najfeld V, Wodarz D, Levy DN, Chen BK. Multiploid inheritance of HIV-1 during cell-to-cell infection. *Journal of virology*. 2011; p. JVI-00231.
- Deleage C**, Wietgreffe SW, Del Prete G, Morcock DR, Hao XP, Piatak Jr M, Bess J, Anderson JL, Perkey KE, Reilly C, et al. Defining HIV and SIV reservoirs in lymphoid tissues. *Pathogens & immunity*. 2016; 1(1):68.
- Domingo E**, Sheldon J, Perales C. Viral quasispecies evolution. *Microbiology and Molecular Biology Reviews*. 2012; 76(2):159–216.
- Duncan CJ**, Russell RA, Sattentau QJ. High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy. *AIDS (London, England)*. 2013; 27(14):2201.

Fletcher CV, Staskus K, Wietgreffe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. *Proc Natl Acad Sci U S A*. 2014; 111(6):2307–12. <https://www.ncbi.nlm.nih.gov/pubmed/24469825>, doi: 10.1073/pnas.1318249111.

Freed EO. HIV-1 replication. *Somatic cell and molecular genetics*. 2001; 26(1-6):13–33.

Froissart R, Wilke CO, Montville R, Remold SK, Chao L, Turner PE. Co-infection weakens selection against epistatic mutations in RNA viruses. *Genetics*. 2004; 168(1):9–19. <https://www.ncbi.nlm.nih.gov/pubmed/15454523>, doi: 10.1534/genetics.104.030205.

Frost SD, Wrin T, Smith DM, Pond SLK, Liu Y, Paxinos E, Chappey C, Galovich J, Beauchaine J, Petropoulos CJ. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. *Proceedings of the National Academy of Sciences*. 2005; 102(51):18514–18519.

Gelderblom HC, Vatakis DN, Burke SA, Lawrie SD, Bristol GC, Levy DN. Viral complementation allows HIV-1 replication without integration. *Retrovirology*. 2008; 5:60. <https://www.ncbi.nlm.nih.gov/pubmed/18613957>, doi: 10.1186/1742-4690-5-60.

Goulder PJ, Brander C, Tang Y, Tremblay C, Colbert RA, Addo MM, Rosenberg ES, Nguyen T, Allen R, Trocha A. Evolution and transmission of stable CTL escape mutations in HIV infection. *Nature*. 2001; 412(6844):334.

Gratton S, Cheynier R, Dumaurier MJ, Oksenhendler E, Wain-Hobson S. Highly restricted spread of HIV-1 and multiply infected cells within splenic germinal centers. *Proceedings of the National Academy of Sciences*. 2000; 97(26):14566–14571.

Groot F, Welsch S, Sattentau QJ. Efficient HIV-1 transmission from macrophages to T cells across transient virological synapses. *Blood, The Journal of the American Society of Hematology*. 2008; 111(9):4660–4663.

Hill AL, Rosenbloom DI, Nowak MA. Evolutionary dynamics of HIV at multiple spatial and temporal scales. *Journal of molecular medicine*. 2012; 90(5):543–561.

Hübner W, McNerney GP, Chen P, Dale BM, Gordon RE, Chuang FY, Li XD, Asmuth DM, Huser T, Chen BK. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. *Science*. 2009; 323(5922):1743–1747.

Iwami S, Takeuchi JS, Nakaoka S, Mammano F, Clavel F, Inaba H, Kobayashi T, Misawa N, Aihara K, Koyanagi Y, et al. Cell-to-cell infection by HIV contributes over half of virus infection. *Elife*. 2015; 4:e08150.

Jackson L, Hunter J, Cele S, Ferreira IM, Young AC, Karim F, Madansein R, Dullabh KJ, Chen CY, Buckels NJ, Ganga Y, Khan K, Boulle M, Lustig G, Neher RA, Sigal A. Incomplete inhibition of HIV infection results in more HIV infected lymph node cells by reducing cell death. *eLife*. 2018; 7:e30134.

Jolly C, Kashefi K, Hollinshead M, Sattentau QJ. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. *Journal of Experimental Medicine*. 2004; 199(2):283–293.

Josefsson L, King MS, Makitalo B, Brännström J, Shao W, Maldarelli F, Kearney MF, Hu WS, Chen J, Gaines H. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. *Proceedings of the National Academy of Sciences*. 2011; 108(27):11199–11204.

Josefsson L, Palmer S, Faria NR, Lemey P, Casazza J, Ambrozak D, Kearney M, Shao W, Kottlil S, Sneller M. Single cell analysis of lymph node tissue from HIV-1 infected patients reveals that the majority of CD4+ T-cells contain one HIV-1 DNA molecule. *PLoS pathogens*. 2013; 9(6):e1003432.

Jung A, Maier R, Vartanian JP, Bocharov G, Jung V, Fischer U, Meese E, Wain-Hobson S, Meyerhans A. Recombination: Multiply infected spleen cells in HIV patients. *Nature*. 2002; 418(6894):144.

Katz RA, Skalka AM. Generation of diversity in retroviruses. *Annu Rev Genet*. 1990; 24:409–45. <https://www.ncbi.nlm.nih.gov/pubmed/1708222>, doi: 10.1146/annurev.ge.24.120190.002205.

Kim JT, Chang E, Sigal A, Baltimore D. Dendritic cells efficiently transmit HIV to T Cells in a tenofovir and raltegravir insensitive manner. *PloS one*. 2018; 13(1):e0189945.

Lauring AS, Frydman J, Andino R. The role of mutational robustness in RNA virus evolution. *Nat Rev Microbiol*. 2013; 11(5):327–36. <https://www.ncbi.nlm.nih.gov/pubmed/23524517>, doi: 10.1038/nrmicro3003.

402 **Law KM**, Komarova NL, Yewdall AW, Lee RK, Herrera OL, Wodarz D, Chen BK. In vivo HIV-1 cell-to-cell transmis-
403 sion promotes multicopy micro-compartmentalized infection. *Cell reports*. 2016; 15(12):2771–2783.

404 **Levy DN**, Aldrovandi GM, Kutsch O, Shaw GM. Dynamics of HIV-1 recombination in its natural target cells.
405 *Proceedings of the National Academy of Sciences*. 2004; 101(12):4204–4209.

406 **Mo H**, Lu L, Pithawalla R, Kempf DJ, Molla A. Complementation in cells cotransfected with a mixture of wild-
407 type and mutant human immunodeficiency virus (HIV) influences the replication capacities and phenotypes
408 of mutant variants in a single-cycle HIV resistance assay. *J Clin Microbiol*. 2004; 42(9):4169–74. <https://www.ncbi.nlm.nih.gov/pubmed/15365007>, doi: 10.1128/JCM.42.9.4169-4174.2004.

409 **Moyano A**, Lustig G, Rodel HE, Antal T, Sigal A. Interference with HIV infection of the first cell is essential for
410 viral clearance at sub-optimal levels of drug inhibition. *PLOS Computational Biology*. 2020; 16(2):e1007482.

411 **Panet A**, Kra-Oz Z. A competition immunoassay for characterizing the reverse transcriptase of mammalian
412 RNA tumor viruses. *Virology*. 1978; 89(1):95–101. <https://www.ncbi.nlm.nih.gov/pubmed/80059>.

413 **Paranjpe S**, Craigo J, Patterson B, Ding M, Barroso P, Harrison L, Montelaro R, Gupta P. Subcompartmentaliza-
414 tion of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital
415 tissues. *AIDS research and human retroviruses*. 2002; 18(17):1271–1280.

416 **Pardons M**, Baxter AE, Massanella M, Pagliuzza A, Fromentin R, Dufour C, Leyre L, Routy JP, Kaufmann DE,
417 Chomont N. Single-cell characterization and quantification of translation-competent viral reservoirs in
418 treated and untreated HIV infection. *PLoS pathogens*. 2019; 15(2):e1007619.

419 **Phillips RE**, Rowland-Jones S, Nixon DF, Gotch FM, Edwards JP, Ogunlesi AO, Elvin JG, Rothbard JA, Bangham
420 CR, Rizza CR. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition.
421 *Nature*. 1991; 354(6353):453.

422 **Rong R**, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, Allen SA, Pinter A, Shaw GM, Hunter E. Escape from
423 autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. *PLoS*
424 *pathogens*. 2009; 5(9):e1000594.

425 **Rosenbloom DI**, Hill AL, Rabi SA, Siliciano RF, Nowak MA. Antiretroviral dynamics determines HIV evolution
426 and predicts therapy outcome. *Nature medicine*. 2012; 18(9):1378.

427 **Rudnicka D**, Feldmann J, Porrot F, Wietgreffe S, Guadagnini S, Prévost MC, Estaquier J, Haase AT, Sol-Foulon
428 N, Schwartz O. Simultaneous cell-to-cell transmission of human immunodeficiency virus to multiple targets
429 through polysynapses. *Journal of virology*. 2009; 83(12):6234–6246.

430 **Samuel R**, Julian MN, Paredes R, Parboosing R, Moodley P, Singh L, Naidoo A, Gordon M. HIV-1 drug resis-
431 tance by ultra-deep sequencing following short course zidovudine, single-dose nevirapine, and single-dose
432 tenofovir with emtricitabine for prevention of mother-to-child transmission. *Journal of acquired immune*
433 *deficiency syndromes (1999)*. 2016; 73(4):384.

434 **Sattentau Q**. Avoiding the void: cell-to-cell spread of human viruses. *Nat Rev Microbiol*. 2008; 6(11):815–26.
435 <https://www.ncbi.nlm.nih.gov/pubmed/18923409>, doi: 10.1038/nrmicro1972.

436 **Schnell G**, Price RW, Swanstrom R, Spudich S. Compartmentalization and clonal amplification of HIV-1 variants
437 in the cerebrospinal fluid during primary infection. *Journal of virology*. 2010; 84(5):2395–2407.

438 **Sherer NM**, Lehmann MJ, Jimenez-Soto LF, Horensavitz C, Pypaert M, Mothes W. Retroviruses can establish
439 filopodial bridges for efficient cell-to-cell transmission. *Nature cell biology*. 2007; 9(3):310.

440 **Sigal A**, Kim JT, Balazs AB, Dekel E, Mayo A, Milo R, Baltimore D. Cell-to-cell spread of HIV permits ongoing
441 replication despite antiretroviral therapy. *Nature*. 2011; 477(7362):95.

442 **Sourisseau M**, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus repli-
443 cation in mobile lymphocytes. *Journal of virology*. 2007; 81(2):1000–1012.

444 **Vignuzzi M**, Stone JK, Arnold JJ, Cameron CE, Andino R. Quasispecies diversity determines pathogenesis through
445 cooperative interactions in a viral population. *Nature*. 2006; 439(7074):344–8. <https://www.ncbi.nlm.nih.gov/pubmed/16327776>, doi: 10.1038/nature04388.

446 **Wodarz D**, Levy DN. Pyroptosis, superinfection, and the maintenance of the latent reservoir in HIV-1 infection.
447 *Scientific reports*. 2017; 7(1):1–10.

- 450 **Wu Y**, Beddall MH, Marsh JW. Rev-dependent indicator T cell line. *Current HIV research*. 2007; 5(4):394–402.
- 451 **Zhong P**, Agosto LM, Ilinskaya A, Dorjbal B, Truong R, Derse D, Uchil PD, Heidecker G, Mothes W. Cell-to-cell
452 transmission can overcome multiple donor and target cell barriers imposed on cell-free HIV. *PloS one*. 2013;
453 8(1):e53138.

Figure S1. Frequency of individual EFV resistance mutants in the face of EFV selection in individual experiments. Combined graph is the mean $\pm$ SEM of individual experiments.

Figure S2. Gating strategy to detect EFV sensitivity of wild type and mutant HIV from singly transfected and co-transfected molecular clones. For single transfections, CFP labelled wildtype and YFP labelled mutant virus was mixed 1:1 before the infection. (A) Uninfected (left panel), CFP wildtype virus only (middle panel) or YFP mutant virus only (right panel) controls. (B) Infection with virus from single transfections mixed 1:1. X-axis is YFP (mutant), y-axis is CFP (wildtype) infected cells. EFV concentration used is shown above each plot. The total frequency of wildtype infected cells is the sum of the frequencies in the upper left and upper right quadrants, while the frequency of mutant infected cells is the sum of the lower right and upper right quadrants. (C) Infection of virus derived from the co-transfection. EFV concentration used is shown above each plot, and gating is as in (B).

Figure S3. Multiple infection is more frequent than expected by chance: Flow cytometry data. Top row shows C7 cells infected with labelled YFP mutant viral supernatant. Middle row shows cells infected with CFP labelled wildtype using an input of infected cells at a dilution shown above each plot. Bottom row shows cells infected with CFP labeled wildtype using the same input of infected cells as the middle row, but with the addition of the same amount of labelled YFP mutant viral supernatant.

Figure S4. Frequency of double infection in PBMCs is higher than theoretically calculated. Three infection conditions, PBMCs alone, PBMCs + Raji cells and PBMCs + Raji-DC cells, were tested for the level of double infection after incubation with CFP and YFP wildtype producing virus. PBMCs and Raji or Raji-DC cells were combined at a 1:2 ratio. Bottom panel is a repeat with different donor PBMCs. The theoretical probability of double infections, as calculated: $[(\text{CFP infection} \times \text{YFP infection}) \times 100] < \text{the experimental values}$.

Figure S5. Experimentally measured values of R_{wt} and R_{mt} . (A) The amount of L100I mutant infected G2 donor cells added to E7 target cells as measured straight after donors were added to targets. (B) Target cell infection after 2 days of incubation with L100I mutant infected donors (A) in the presence of different drug concentrations. (C) The amount of wildtype infected G2 donor cells added to E7 target cells as measured straight after donors were added to targets. (D) Target cell wildtype infection after 2 days of incubation with wildtype infected donors (C) in the presence of different drug concentrations. Red squares highlight donors added for (A) and (C) and live infected targets for (B) and (D).

Table S1. Replication ratio of mutant virus

Efavirenz conc (nM)	Donors added $\pm$ s.d. (cells/ml) ^a	Live infected targets $\pm$ s.d. (cells/ml) ^a	Replication ratio $\pm$ s.d. (R_{mt}) ^b
0	1531 $\pm$ 471	370968 $\pm$ 66095	251 $\pm$ 29
10	1531 $\pm$ 471	316339 $\pm$ 67893	212 $\pm$ 26
20	1531 $\pm$ 471	237123 $\pm$ 38000	162 $\pm$ 27
40	1531 $\pm$ 471	171357 $\pm$ 23609	117 $\pm$ 19
80	1531 $\pm$ 471	79403 $\pm$ 5868	55 $\pm$ 11
160	1531 $\pm$ 471	44423 $\pm$ 7156	30 $\pm$ 5

^a cells/ml calculated as [(# of cells acquired x flow rate) / time taken to acquire]

^b R_{mt} calculated as [live infected targets/ml / donors added/ml]

Table S2. Replication ratio of wildtype virus

Efavirenz conc (nM)	Donors added (cells/ml) ^a	Live infected targets (cells/ml) ^a	Replication ratio (R_{wt}) ^b
0	1767 ± 330	477024 ± 20428	278 ± 42
4	1767 ± 330	209512 ± 25384	121 ± 14
8	1767 ± 330	106417 ± 7348	62 ± 10
16	1767 ± 330	50598 ± 4901	29 ± 5
32	1767 ± 330	27821 ± 4029	16 ± 4
64	1767 ± 330	15780 ± 5423	9 ± 3

^a cells/ml calculated as [(# of cells acquired x flow rate) / time taken to acquire]

^b R_{wt} calculated as [live infected targets/ml / donors added/ml]